Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21565891 | 0.79 | TSHR (0.34) | TSHR | |
| SCHEMBL20315049 | 0.79 | TSHR (0.37) | TSHR | |
| SCHEMBL20314966 | 0.78 | TSHR (0.36) | TSHR | |
| SCHEMBL20314940 | 0.78 | TSHR (0.36) | TSHR | |
| SCHEMBL24952584 | 0.77 | PARP1 (0.31) | — | |
| SCHEMBL24448353 | 0.75 | TSHR (0.33) | TSHR | |
| SCHEMBL19019111 | 0.74 | — | — | |
| SCHEMBL25762330 | 0.71 | TSHR (0.39) | TSHR | |
| SCHEMBL20326224 | 0.70 | TSHR (0.37) | TSHR | |
| SCHEMBL8446682 | 0.69 | TSHR (0.40) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11045484-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-02-20 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| WO-2018119183-A2 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | DHFR, TYMS, TYMP | TSHR 2226/4885 |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4187/4885 |
| US-11045484-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | TSHR 4359/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | TSHR 4488/4885 |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | TSHR 4359/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4359/4885 |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.